• Kartik K Venkatesh, Allison K DeLong, Rami Kantor, Stacey Chapman, Jessica Ingersoll, Jaclynn Kurpewski, Maria Pia De Pasquale, Richard D'Aquila, Angela M Caliendo, and Susan Cu-Uvin.
• Department of Obstetrics and Gynecology, Women & Infants Hospital of Rhode Island, Alpert Medical School, Brown University, Providence, RI, USA. Kartik_Venkatesh@Brown.edu
• J Womens Health (Larchmt). 2013 Apr 1; 22 (4): 330-8.

ObjectiveTo longitudinally assess the association between plasma viral load (PVL) and genital tract human immunodeficiency virus (GT HIV) RNA among HIV-1 infected women changing highly active antiretroviral therapy (HAART) because of detectable PVL on current treatment.MethodsWomen were eligible for the study if they had detectable PVL (defined as two consecutive samples with PVL>1000 copies/mL) and intended to change their current HAART regimen at the time of enrollment. Paired plasma and GT HIV-1 RNA were measured prospectively over 3 years. Longitudinal analyses examined rates of GT HIV-1 RNA shedding and the association with PVL.ResultsSixteen women were followed for a median of 11 visits contributing a total of 205 study visits. At study enrollment, all had detectable PVL and 69% had detectable GT HIV-1 RNA. Half of the women changed to a new HAART regimen with ≥3 active antiretroviral drugs. The probability of having detectable PVL ≥30 days after changing HAART was 0.56 (95% CI: 0.37 to 0.74). Fourteen women (88%) had detectable PVL on a follow-up visit ≥30 or 60 days after changing HAART; and 12 women (75%) had detectable GT HIV-1 RNA on a follow-up visit ≥30 or 60 days after changing HAART. When PVL was undetectable, GT shedding occurred at 11% of visits, and when PVL was detectable, GT shedding occurred at 47% of visits.ConclusionsSome treatment-experienced HIV-infected women continue to have detectable virus in both the plasma and GT following a change in HAART, highlighting the difficulty of viral suppression in this patient population.

28 keywords...

hide…